Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-Deazaguanine is a synthetic analog of guanine and a small molecule inhibitor of purine nucleoside phosphorylase (PNP), with a dissociation constant (Kd) of approximately 160 nM. As an experimental compound, it has been primarily used in research settings to study nucleic acid structure and function, as well as to develop potential antiviral, antineoplastic, and immunosuppressive agents. Inhibitors of PNP like 9-deazaguanine are known to suppress T cell proliferation and have been investigated for their potential use in treating T cell cancers, autoimmune diseases, transplant rejection, psoriasis, and gout. The mechanism involves competitive inhibition at the PNP enzyme active site; this disrupts purine metabolism critical for lymphocyte proliferation. While its exact mechanism is still under investigation, it may also interfere with guanine binding in nucleic acids or proteins and impede DNA/RNA replication[5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 9-deazaguanine.